Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients
NCT ID: NCT01414777
Last Updated: 2022-03-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2/PHASE3
Total Enrollment
68 participants
Study Classification
INTERVENTIONAL
Study Start Date
2009-11-30
Study Completion Date
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that given prophylactically, intravenous ondansetron will attenuate the drop in blood pressure and heart rate frequently seen after spinal anesthesia.
Eighty-six American Society of Anesthesiologists (ASA) physical status I or II in preoperative patient assessment, parturients age of 18 to 45 years scheduled to undergo elective caesarean section will be enrolled.
Patients will be randomized to 2 groups: the ondansetron group, receiving 8 mg intravenous ondansetron diluted in 10 mL of saline; or the placebo group, who were administered 10 mL of saline given 5 minutes prior to performing the spinal anesthetic. Investigational Pharmacy will randomize and dispense study drug.
Baseline measurements of vital signs will be taken. Otherwise standard management will then be used:
* Patients must be NPO for 8 hours
* Pulse oximetry, EKG monitoring, noninvasive blood pressure at a minimum of every 3 minutes, more frequently if decided by the provider.
* Standard lumbar puncture in a sitting position the L3-L4 or L4-L5
* Whitacre pencil-point, 25 gauge
* Injectate: 2 mL of 0.75% hyperbaric bupivacaine, 100 mcg preservative free morphine, 20 mcg fentanyl
* Immediately after completing the subarachnoid injection, patients will be laid supine with left lateral uterine displacement
The sensory level of anesthesia will be assessed in the standard fashion every five minutes using ice. The motor component will tested using the Bromage scale for spinal anesthesia (0, no paralysis; 1, inability to lift the thigh \[only knee/feet\]; 2, inability to flex the knee \[only feet\]; 3, inability to move any joint in the legs).
Eighty-six American Society of Anesthesiologists (ASA) physical status I or II in preoperative patient assessment, parturients age of 18 to 45 years scheduled to undergo elective caesarean section will be enrolled.
Patients will be randomized to 2 groups: the ondansetron group, receiving 8 mg intravenous ondansetron diluted in 10 mL of saline; or the placebo group, who were administered 10 mL of saline given 5 minutes prior to performing the spinal anesthetic. Investigational Pharmacy will randomize and dispense study drug.
Baseline measurements of vital signs will be taken. Otherwise standard management will then be used:
* Patients must be NPO for 8 hours
* Pulse oximetry, EKG monitoring, noninvasive blood pressure at a minimum of every 3 minutes, more frequently if decided by the provider.
* Standard lumbar puncture in a sitting position the L3-L4 or L4-L5
* Whitacre pencil-point, 25 gauge
* Injectate: 2 mL of 0.75% hyperbaric bupivacaine, 100 mcg preservative free morphine, 20 mcg fentanyl
* Immediately after completing the subarachnoid injection, patients will be laid supine with left lateral uterine displacement
The sensory level of anesthesia will be assessed in the standard fashion every five minutes using ice. The motor component will tested using the Bromage scale for spinal anesthesia (0, no paralysis; 1, inability to lift the thigh \[only knee/feet\]; 2, inability to flex the knee \[only feet\]; 3, inability to move any joint in the legs).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hemodynamic Protection of Preoperative Ondansetron 15 Minutes Before Spinal Anaesthesia in Caesarean Section
NCT04140058
Hypotension
Nausea
Vomiting
COMPLETED
PHASE3
Interest of Intravenous Ondansetron in the Prevention of Spinal Anaesthesia-induced Hypotension in Caesarean Section
NCT02862873
Hypotension
TERMINATED
NA
ONDANSETRON AND EFFECTIVE DOSE IN 50% OF SUBJECTS OF PROPHYLACTIC NOREPINEPHRINE INFUSIONS FOR PREVENTING SPINAL ANESTHESIA-INDUCED HYPOTENSION DURING CESAREAN DELIVERY
NCT04703088
Hypotension
Anesthesia; Adverse Effect, Spinal and Epidural
Cesarean Section
UNKNOWN
PHASE3
The Effect of Preventive Use of Ondansetron in the Cesarean Section Under Spinal Anesthesia
NCT02883192
Adverse Anesthesia Outcome
UNKNOWN
NA
Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension
NCT02101047
Complications; Cesarean Section
Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
WITHDRAWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Over the last 30 years, regional anesthesia has emerged as the method of choice for elective caesarean section because it avoids risks involved in managing the airway of the parturient and has the added significant benefit of mother being awake for the birth of her child. Indeed, this changing practice patterns is thought to have lead to a significant drop in anesthesia related maternal morbidity and mortality.
At the same time, regional anesthesia is associated with both minor and significant risk.
Most common among these effects is hypotension and bradycardia, occurring in 33% and 13% of cases, respectively. In the pregnant patient, supine positioning required for surgery is associated hypotension due to aortocaval compression by the gravid uterus in 8% of patients, even without spinal anesthesia. During caesarean section, the combination of these factors can lead to hypotension include decreased placental blood flow, impaired fetal oxygenation and fetal acidosis. Maternal symptoms of low blood pressures include nausea, vomiting, dizziness, and decreased consciousness. This situation has lead to dozens of publications seeking to prevent or minimize the hypotensive response.
Hypotension after a spinal is initially due to a blockade of sympathetic fibers leading to a drop in systemic vascular resistance. Spinal-induced bradycardia is multifactorial but is in part due to the Bezold-Jarisch Reflex (BJR). This reflex is mediated by serotonin receptors within the wall of the ventricle in response to systemic hypotension. These receptors, the 5HT3 subtype, cause an increase efferent vagal signaling when bound by serotonin released during hypovolemic states, clinically leading to bradycardia and further hypotension.
Ondansetron, a widely used anti-emetic and serotonin antagonist, has been safely used to blunt the BJR, resulting in less bradycardia and hypotension first in animals and later in humans undergoing spinal anesthesia. ,
Use During Pregnancy:
The FDA labels ondansetron as a class B. Studies in pregnant rats and rabbits at doses up to 70 times higher than clinically used doses revealed no evidence of impaired fertility or harm to the fetus due to ondansetron. There are, however, few prospective studies in pregnant women. Nevertheless, the drug is widely used has a long safety history for use in pregnancy and during anesthesia for caesarean section.
At the same time, regional anesthesia is associated with both minor and significant risk.
Most common among these effects is hypotension and bradycardia, occurring in 33% and 13% of cases, respectively. In the pregnant patient, supine positioning required for surgery is associated hypotension due to aortocaval compression by the gravid uterus in 8% of patients, even without spinal anesthesia. During caesarean section, the combination of these factors can lead to hypotension include decreased placental blood flow, impaired fetal oxygenation and fetal acidosis. Maternal symptoms of low blood pressures include nausea, vomiting, dizziness, and decreased consciousness. This situation has lead to dozens of publications seeking to prevent or minimize the hypotensive response.
Hypotension after a spinal is initially due to a blockade of sympathetic fibers leading to a drop in systemic vascular resistance. Spinal-induced bradycardia is multifactorial but is in part due to the Bezold-Jarisch Reflex (BJR). This reflex is mediated by serotonin receptors within the wall of the ventricle in response to systemic hypotension. These receptors, the 5HT3 subtype, cause an increase efferent vagal signaling when bound by serotonin released during hypovolemic states, clinically leading to bradycardia and further hypotension.
Ondansetron, a widely used anti-emetic and serotonin antagonist, has been safely used to blunt the BJR, resulting in less bradycardia and hypotension first in animals and later in humans undergoing spinal anesthesia. ,
Use During Pregnancy:
The FDA labels ondansetron as a class B. Studies in pregnant rats and rabbits at doses up to 70 times higher than clinically used doses revealed no evidence of impaired fertility or harm to the fetus due to ondansetron. There are, however, few prospective studies in pregnant women. Nevertheless, the drug is widely used has a long safety history for use in pregnancy and during anesthesia for caesarean section.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypotension
Pregnancy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ondansetron
ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
Group Type
EXPERIMENTAL
ondansetron
Intervention Type
DRUG
Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
Placebo
Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
Group Type
PLACEBO_COMPARATOR
placebo
Intervention Type
DRUG
placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ondansetron
Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
Intervention Type
DRUG
placebo
placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
epidural
epidural
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elective Caesarean section
* Consent to be in the study
* Age 18-45
* ASA 1 or 2
* Consent to be in the study
* Age 18-45
* ASA 1 or 2
Exclusion Criteria
* Patient refusal
* Patients with known allergy to ondansetron will be excluded
* Contraindications to spinal anesthetic
* Known Coagulopathy (acquired e.g. anticoagulation or existing such as liver disease; using patient history, physical examination to determine bleeding risks, a platelet count under 100 or a PT INR over 1.4)
* Severely altered anatomy (e.g. post surgical changes)
* Existing neurological deficits (Women with a history of migraine or tension headache will be allowed to enroll. More severe conditions with daily life limiting symptoms will be excluded. Examples include epilepsy, pseudotumor cerebri, prior stroke with persistent neurologic deficits, or any motor or sensory neuropathy with existing deficits)
* Skin infection overlying site
* Patients with known allergy to ondansetron will be excluded
* Contraindications to spinal anesthetic
* Known Coagulopathy (acquired e.g. anticoagulation or existing such as liver disease; using patient history, physical examination to determine bleeding risks, a platelet count under 100 or a PT INR over 1.4)
* Severely altered anatomy (e.g. post surgical changes)
* Existing neurological deficits (Women with a history of migraine or tension headache will be allowed to enroll. More severe conditions with daily life limiting symptoms will be excluded. Examples include epilepsy, pseudotumor cerebri, prior stroke with persistent neurologic deficits, or any motor or sensory neuropathy with existing deficits)
* Skin infection overlying site
Minimum Eligible Age
18 Years
Maximum Eligible Age
45 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Virginia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Tiouririne, MD
Associate Professor of Anesthesiology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jordan Hackworth, MD
Role: PRINCIPAL_INVESTIGATOR
University of Virginia Anesthesiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia Health System
Charlottesville, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Hawkins JL. Anesthesia-related maternal mortality. Clin Obstet Gynecol. 2003 Sep;46(3):679-87. doi: 10.1097/00003081-200309000-00020. No abstract available.
Reference Type
BACKGROUND
Mhyre JM, Riesner MN, Polley LS, Naughton NN. A series of anesthesia-related maternal deaths in Michigan, 1985-2003. Anesthesiology. 2007 Jun;106(6):1096-104. doi: 10.1097/01.anes.0000267592.34626.6b.
Reference Type
BACKGROUND
Lee LA, Posner KL, Domino KB, Caplan RA, Cheney FW. Injuries associated with regional anesthesia in the 1980s and 1990s: a closed claims analysis. Anesthesiology. 2004 Jul;101(1):143-52. doi: 10.1097/00000542-200407000-00023.
Reference Type
BACKGROUND
Liu SS, McDonald SB. Current issues in spinal anesthesia. Anesthesiology. 2001 May;94(5):888-906. doi: 10.1097/00000542-200105000-00030. No abstract available.
Reference Type
BACKGROUND
Jackson R, Reid JA, Thorburn J. Volume preloading is not essential to prevent spinal-induced hypotension at caesarean section. Br J Anaesth. 1995 Sep;75(3):262-5. doi: 10.1093/bja/75.3.262.
Reference Type
BACKGROUND
Kinsella SM, Lohmann G. Supine hypotensive syndrome. Obstet Gynecol. 1994 May;83(5 Pt 1):774-88.
Reference Type
BACKGROUND
Rout CC, Rocke DA. Prevention of hypotension following spinal anesthesia for cesarean section. Int Anesthesiol Clin. 1994 Spring;32(2):117-35. No abstract available.
Reference Type
BACKGROUND
Mathru M, Rao TL, Kartha RK, Shanmugham M, Jacobs HK. Intravenous albumin administration for prevention of spinal hypotension during cesarean section. Anesth Analg. 1980 Sep;59(9):655-8.
Reference Type
BACKGROUND
Dahlgren G, Granath F, Pregner K, Rosblad PG, Wessel H, Irestedt L. Colloid vs. crystalloid preloading to prevent maternal hypotension during spinal anesthesia for elective cesarean section. Acta Anaesthesiol Scand. 2005 Sep;49(8):1200-6. doi: 10.1111/j.1399-6576.2005.00730.x.
Reference Type
BACKGROUND
Ueyama H, He YL, Tanigami H, Mashimo T, Yoshiya I. Effects of crystalloid and colloid preload on blood volume in the parturient undergoing spinal anesthesia for elective Cesarean section. Anesthesiology. 1999 Dec;91(6):1571-6. doi: 10.1097/00000542-199912000-00006.
Reference Type
BACKGROUND
Riley ET, Cohen SE, Rubenstein AJ, Flanagan B. Prevention of hypotension after spinal anesthesia for cesarean section: six percent hetastarch versus lactated Ringer's solution. Anesth Analg. 1995 Oct;81(4):838-42. doi: 10.1097/00000539-199510000-00031.
Reference Type
BACKGROUND
Campagna JA, Carter C. Clinical relevance of the Bezold-Jarisch reflex. Anesthesiology. 2003 May;98(5):1250-60. doi: 10.1097/00000542-200305000-00030. No abstract available.
Reference Type
BACKGROUND
Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007 Oct;376(1-2):45-63. doi: 10.1007/s00210-007-0179-1. Epub 2007 Aug 17.
Reference Type
BACKGROUND
Veelken R, Sawin LL, DiBona GF. Epicardial serotonin receptors in circulatory control in conscious Sprague-Dawley rats. Am J Physiol. 1990 Feb;258(2 Pt 2):H466-72. doi: 10.1152/ajpheart.1990.258.2.H466.
Reference Type
BACKGROUND
Owczuk R, Wenski W, Polak-Krzeminska A, Twardowski P, Arszulowicz R, Dylczyk-Sommer A, Wujtewicz MA, Sawicka W, Morzuch E, Smietanski M, Wujtewicz M. Ondansetron given intravenously attenuates arterial blood pressure drop due to spinal anesthesia: a double-blind, placebo-controlled study. Reg Anesth Pain Med. 2008 Jul-Aug;33(4):332-9. doi: 10.1016/j.rapm.2008.01.010.
Reference Type
BACKGROUND
Martinek RM. Witnessed asystole during spinal anesthesia treated with atropine and ondansetron: a case report. Can J Anaesth. 2004 Mar;51(3):226-30. doi: 10.1007/BF03019100.
Reference Type
BACKGROUND
FDA Prescribing Information. Web retrieved 7/8/2009 .http://www.fda.org
Reference Type
BACKGROUND
Tucker ML, Jackson MR, Scales MD, Spurling NW, Tweats DJ, Capel-Edwards K. Ondansetron: pre-clinical safety evaluation. Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S79-93.
Reference Type
BACKGROUND
Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG. 2004 Sep;111(9):940-3. doi: 10.1111/j.1471-0528.2004.00236.x.
Reference Type
BACKGROUND
Sullivan CA, Johnson CA, Roach H, Martin RW, Stewart DK, Morrison JC. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol. 1996 May;174(5):1565-8. doi: 10.1016/s0002-9378(96)70607-5.
Reference Type
BACKGROUND
Kuscu NK, Koyuncu F. Hyperemesis gravidarum: current concepts and management. Postgrad Med J. 2002 Feb;78(916):76-9. doi: 10.1136/pmj.78.916.76.
Reference Type
BACKGROUND
Asker C, Norstedt Wikner B, Kallen B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol. 2005 Dec;61(12):899-906. doi: 10.1007/s00228-005-0055-1. Epub 2005 Nov 18.
Reference Type
BACKGROUND
Phillips TW Jr, Broussard DM, Sumrall WD 3rd, Hart SR. Intraoperative oxygen administration does not reduce the incidence or severity of nausea or vomiting associated with neuraxial anesthesia for cesarean delivery. Anesth Analg. 2007 Oct;105(4):1113-7, table of contents. doi: 10.1213/01.ane.0000278626.54116.0e.
Reference Type
BACKGROUND
Siddik-Sayyid SM, Aouad MT, Taha SK, Azar MS, Hakki MA, Kaddoum RN, Nasr VG, Yazbek VG, Baraka AS. Does ondansetron or granisetron prevent subarachnoid morphine-induced pruritus after cesarean delivery? Anesth Analg. 2007 Feb;104(2):421-4. doi: 10.1213/01.ane.0000253668.10453.de.
Reference Type
BACKGROUND
Yeh HM, Chen LK, Lin CJ, Chan WH, Chen YP, Lin CS, Sun WZ, Wang MJ, Tsai SK. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesth Analg. 2000 Jul;91(1):172-5. doi: 10.1097/00000539-200007000-00032.
Reference Type
BACKGROUND
Yazigi A, Chalhoub V, Madi-Jebara S, Haddad F, Hayek G. Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine. J Clin Anesth. 2002 May;14(3):183-6. doi: 10.1016/s0952-8180(01)00381-6.
Reference Type
BACKGROUND
Sarvela PJ, Halonen PM, Soikkeli AI, Kainu JP, Korttila KT. Ondansetron and tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus in elective cesarean delivery. Acta Anaesthesiol Scand. 2006 Feb;50(2):239-44. doi: 10.1111/j.1399-6576.2006.00934.x.
Reference Type
BACKGROUND
Abouleish EI, Rashid S, Haque S, Giezentanner A, Joynton P, Chuang AZ. Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia. Anaesthesia. 1999 May;54(5):479-82. doi: 10.1046/j.1365-2044.1999.00798.x.
Reference Type
BACKGROUND
George RB, Allen TK, Habib AS. Serotonin receptor antagonists for the prevention and treatment of pruritus, nausea, and vomiting in women undergoing cesarean delivery with intrathecal morphine: a systematic review and meta-analysis. Anesth Analg. 2009 Jul;109(1):174-82. doi: 10.1213/ane.0b013e3181a45a6b.
Reference Type
BACKGROUND
Tang J, Wang B, White PF, Watcha MF, Qi J, Wender RH. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg. 1998 Feb;86(2):274-82. doi: 10.1097/00000539-199802000-00010.
Reference Type
BACKGROUND
Terkawi AS, Tiouririne M, Mehta SH, Hackworth JM, Tsang S, Durieux ME. Ondansetron Does Not Attenuate Hemodynamic Changes in Patients Undergoing Elective Cesarean Delivery Using Subarachnoid Anesthesia: A Double-Blind, Placebo-Controlled, Randomized Trial. Reg Anesth Pain Med. 2015 Jul-Aug;40(4):344-8. doi: 10.1097/AAP.0000000000000274.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14583
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section
NCT03931863
UNKNOWN
PHASE3
Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study
NCT02654847
COMPLETED
NA
Role of Ondansetron in Spinal Anaesthesia Induced Hypotension
NCT06727201
NOT_YET_RECRUITING
PHASE2/PHASE3
Norepinephrine Consumption After Prophylactic Ondansetron
NCT02928601
COMPLETED
PHASE4
Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery
NCT02354833
COMPLETED
PHASE4
Ondansetron for Postspinal Anesthesia Hypotension
NCT05475873
COMPLETED
NA
Ephedrine Versus Ondansetron During Cesarean Delivery
NCT05127876
COMPLETED
PHASE4
Effects of Ondansetron on Hemodynamics in Cesarean Section Under Spinal Anesthesia
NCT03629522
COMPLETED
PHASE4
The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries
NCT01841606
COMPLETED
PHASE2
Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section
NCT02194192
COMPLETED
NA
Contribution of Ondansetron to Preventing Post-Dural Puncture Headaches Following Spinal Anesthesia
NCT06444737
RECRUITING
NA
Ondansetron Prior Spinal Anaesthesia
NCT06431568
COMPLETED
Reduction in Spinal-induced Hypotension With Ondansetron in Parturients Undergoing Caesarean Section
NCT02913768
COMPLETED
PHASE4
Lingual Ondansetron in Reduction of Spinal Hypotension in Cesarean Section
NCT07037654
ACTIVE_NOT_RECRUITING
NA
Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia
NCT02854787
COMPLETED
PHASE4
Phenylephrine in Spinal Anesthesia in Preeclamptic Patients
NCT00458003
COMPLETED
NA
Ideal Dose of Phenylephrine to Treat Low Blood Pressure During Cesarean Section
NCT00379691
COMPLETED
NA
Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension
NCT04272567
COMPLETED
NA
Prophylactic Norepinephrine Infusion Combined With Colloid Coloading for Postspinal Anesthesia Hypotension
NCT05133817
COMPLETED
NA
Norepinephrine on Maternal Hypotension After Combined Lumbar and Epidural Anaesthesia
NCT06498115
RECRUITING
PHASE4
A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries
NCT02962986
COMPLETED
NA
Norepinephrine or Phenylephrine in Bolus for Hypotension in Cesarean Delivery
NCT03702400
COMPLETED
PHASE2
Norepinephrine and Phenylephrine for Maternal Cardiac Output During Spinal Anesthesia for Elective Cesarean Delivery
NCT02969239
UNKNOWN
PHASE4
90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients
NCT06151470
NOT_YET_RECRUITING
NA
90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients
NCT06151457
NOT_YET_RECRUITING
NA